Hepatitis C virus cell entry: a target for novel antiviral strategies to address limitations of direct acting antivirals.
Ontology highlight
ABSTRACT: Hepatitis C virus (HCV) infection remains a major global health problem, with 130-170 million chronically infected individuals at risk to develop severe liver disease, including hepatocellular carcinoma. Although the development of direct-acting antivirals offers cure for a large majority of patients, there are still a number of clinical challenges. These include DAA failure in a significant subset of patients, difficult-to-treat genotypes and limited access to therapy due to high costs. Moreover, recent data indicate that the risk for liver cancer persists in patients with advanced fibrosis. These challenges highlight the need for continued efforts towards novel therapeutic strategies for HCV. Over the past two decades, advances in HCV model systems have enabled a detailed understanding o
SUBMITTER: Colpitts CC
PROVIDER: S-EPMC7613477 | biostudies-literature | 2016 Sep
REPOSITORIES: biostudies-literature
ACCESS DATA